Literature DB >> 4087023

Morphometric effects of vincristine on nerve regeneration in the rat.

S Shiraishi, P M Le Quesne, T Gajree, J B Cavanagh.   

Abstract

Administration of vincristine (200, 100 or 50 micrograms/kg/week) for 6 months during regeneration of the sciatic nerve after crush injury caused a dose-dependent reduction in nerve fibre size and failure of removal of myelin debris. Successfully regenerating neurites showed an unusual amount of shape distortion. The ratio of myelin sheath thickness to axon circumference was reduced, but the ratio of myelin sheath thickness to axon area was normal. Microtubule concentration was diminished in axons, but neurofilament density was unaffected. Unmyelinated axons were reduced in number but their axon diameter distribution was not affected. Fibres on the non-crushed side appeared normal. The toxicity of vincristine to regenerating nerves is probably related to increased blood-nerve permeability occurring both at the site of crush and along the degenerating nerve.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087023     DOI: 10.1016/0022-510x(85)90057-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Live imaging of neural structure and function by fibred fluorescence microscopy.

Authors:  Pierre Vincent; Uwe Maskos; Igor Charvet; Laurence Bourgeais; Luc Stoppini; Nathalie Leresche; Jean-Pierre Changeux; Régis Lambert; Paolo Meda; Danièle Paupardin-Tritsch
Journal:  EMBO Rep       Date:  2006-09-29       Impact factor: 8.807

2.  Prevention of post-traumatic reinnervation with microtubule inhibitors.

Authors:  Andrea M Park; Reena Dhanda Patil; Randal C Paniello
Journal:  Laryngoscope       Date:  2015-07-06       Impact factor: 3.325

3.  Retardation of rat sciatic nerve regeneration after local application of minute doses of vincristine.

Authors:  G S Ruigt; M H den Brok
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.